OPKO Health (NASDAQ:OPK - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09, Zacks reports. The business had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.
OPKO Health Price Performance
OPK traded up $0.01 during trading on Monday, hitting $1.75. The company's stock had a trading volume of 29,653,360 shares, compared to its average volume of 4,457,309. The firm's 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.55. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health has a 12 month low of $0.86 and a 12 month high of $1.84. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -9.21 and a beta of 1.63.
Wall Street Analysts Forecast Growth
Several research firms recently commented on OPK. Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday. HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Monday. Finally, StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday.
Check Out Our Latest Stock Report on OPKO Health
Insider Buying and Selling at OPKO Health
In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $1.59 per share, with a total value of $198,750.00. Following the purchase, the chief executive officer now owns 212,536,477 shares of the company's stock, valued at approximately $337,932,998.43. This represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders acquired 1,389,971 shares of company stock worth $2,124,442. 47.26% of the stock is currently owned by insiders.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
See Also
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
